Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Reduced susceptibility to daptomycin has been reported in patients with infections due to methicillin-resistant Staphylococcus aureus (MRSA). Although infections with daptomycin-nonsusceptible (DNS) MRSA are infrequent, optimal therapy of these strains has not been determined. We investigated the killing effects of novel antibiotic combinations with daptomycin (DAP) against two clinical DNS MRSA isolates (SA-684 and R6003) in a 72-h in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations (SEV). Simulated regimens included DAP at 6 mg/kg every 24 h (q24h) alone or in combination with trimethoprim-sulfamethoxazole (TMP/SMX) at 160/800 mg q12h, linezolid (LIN) at 600 mg q12h, cefepime (CEF) at 2 g q12h, and nafcillin (NAF) at 4 g q4h. Bactericidal activity was defined as a ≥3-log 10 CFU/g kill. Differences in CFU/g were evaluated between 4 and 72 h by analysis of variance with the Bonferroni post hoc test. DAP MICs were 4 and 2 mg/liter for SA-684 and R6003, respectively. In the PK/PD model, DAP alone was slowly bactericidal, achieving a 3-log 10 kill at 24 and 50 h for SA-684 and R6003, respectively. Against SA-684, DAP plus TMP/SMX, CEF, LIN, or NAF was bactericidal at 4, 4, 8, and 8 h, respectively, and maintained this activity for the 72-h study duration. DAP plus TMP/SMX or CEF exhibited superior killing than DAP alone against SA-684 between 4 and 72 h, and overall this was significant ( P < 0.05). Against R6003, DAP plus TMP/SMX was bactericidal (8 h) and superior to DAP alone between 8 and 72 h ( P < 0.001). The unique combination of DAP plus TMP/SMX was the most effective and rapidly bactericidal regimen against the two isolates tested and may provide a clinical option to treat DNS S. aureus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In an in vitro study, 167 the addition of trimethoprim-sulfamethoxazole to daptomycin was rapidly bactericidal for a daptomycin-nonsusceptible strain compared with daptomycin monotherapy.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
In Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370
Benvenuto, M., Benziger, D. P., Yankelev, S., & Vigliani, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00247-06 · Cited by 319
Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., & Bayer, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00719-07 · Cited by 318
LaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
Self-citationResistance Studies with Daptomycin
Silverman, J. A., Oliver, N., Andrew, T., & Li, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1799-1802.2001 · Cited by 234
Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses
Gee, T., Ellis, R., Marshall, G., Andrews, J., Ashby, J., & Wise, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1843-1846.2001 · Cited by 220
Mishra, N. N., Yang, S.-J., Sawa, A., Rubio, A., Nast, C. C., Yeaman, M. R., & Bayer, A. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01682-08 · Cited by 216
Akins, R. L., & Rybak, M. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.454-459.2001 · Cited by 179
Self-citation
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationMehta, S., Singh, C., Plata, K. B., Chanda, P. K., Paul, A., Riosa, S., Rosato, R. R., & Rosato, A. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-12 · Cited by 142
Werth, B. J., Sakoulas, G., Rose, W. E., Pogliano, J., Tewhey, R., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-12 · Cited by 134
Self-citation
Metadata
- Authors
- Steed, M. E., Vidaillac, C., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences
- Corresponding author
- Rybak, Michael J.
- ORCID
- Rybak, Michael J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-12
- Volume
- 54
- Issue
- 12
- Pages
- 5187-5192
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2981245
- OpenAlex
- W2119458993
- Semantic Scholar
- 7552241d2c0272dbc6241c2ed1bc943545f21add
- Cited by
- 57
- References
- 37
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 8 · 2014: 4 · 2013: 5 · 2012: 7
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- KU ScholarWorks (The University of Kansas) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- daptomycin, methicillin-resistant Staphylococcus aureus, antibiotic combinations, bactericidal activity, pharmacokinetic-pharmacodynamic modeling, trimethoprim-sulfamethoxazole, linezolid, cefepime, nafcillin, endocarditis
- MeSH terms
- Linezolid, Cefepime, Acetamides, Anti-Infective Agents, Cephalosporins, Drug Combinations, Endocarditis, Bacterial, Microbial Sensitivity Tests, Nafcillin, Trimethoprim, Sulfamethoxazole Drug Combination, Daptomycin, Oxazolidinones, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations. https://app.cochat.ai/papers/10.1128/aac.00536-10
- The paper
- Steed, M. E., Vidaillac, C., & Rybak, M. J. (2010). Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00536-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.